candesartan has been researched along with Neoplasms in 10 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the present study was to clarify the influence of candesartan-based therapy on subsequent carcinogenesis and cancer death in patients with coronary artery disease with hypertension in a substudy of a multicenter, prospective, randomized, controlled trial." | 9.16 | Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). ( Hagiwara, N; Koyanagi, R; Ogawa, H; Oka, T; Sugiura, R, 2012) |
| "The aim of the present study was to clarify the influence of candesartan-based therapy on subsequent carcinogenesis and cancer death in patients with coronary artery disease with hypertension in a substudy of a multicenter, prospective, randomized, controlled trial." | 5.16 | Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). ( Hagiwara, N; Koyanagi, R; Ogawa, H; Oka, T; Sugiura, R, 2012) |
| "Incident cancer cases were compared in patients randomized to ARBs versus controls." | 2.47 | Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ( , 2011) |
| "Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26." | 2.47 | Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. ( Chang, CH; Lai, MS; Lin, JW; Wu, LC, 2011) |
| "A multifunctional copolymer-anticancer conjugate chitosan-graft-polyethyleneimine-candesartan (CPC) containing low molecular weight chitosan (CS) backbone and polyethyleneimine (PEI) arms with candesartan (CD) conjugated via an amide bond was fabricated as a targeted co-delivery nanovector of drug and gene for potential cancer therapy." | 1.40 | A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy. ( Bao, X; Ding, Y; Jin, Y; Wang, C; Wang, W; Wang, X; Wang, Y; Zhou, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, X | 1 |
| Su, Y | 1 |
| Wang, C | 2 |
| Zhang, F | 1 |
| Chen, K | 1 |
| Wang, Y | 2 |
| Li, M | 1 |
| Wang, W | 2 |
| Bao, X | 1 |
| Zhou, J | 1 |
| Ding, Y | 1 |
| Wang, X | 1 |
| Jin, Y | 1 |
| Roix, JJ | 1 |
| Harrison, SD | 1 |
| Rainbolt, EA | 1 |
| Meshaw, KR | 1 |
| McMurry, AS | 1 |
| Cheung, P | 1 |
| Saha, S | 1 |
| Kihara, K | 1 |
| Kamimura, H | 1 |
| Isayama, H | 1 |
| Fujii, Y | 1 |
| Iino, Y | 1 |
| Chang, CH | 1 |
| Lin, JW | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Sugiura, R | 1 |
| Ogawa, H | 1 |
| Oka, T | 1 |
| Koyanagi, R | 1 |
| Hagiwara, N | 1 |
| Möller, BH | 1 |
| Cazaubon, S | 1 |
| Deshayes, F | 1 |
| Couraud, PO | 1 |
| Nahmias, C | 1 |
| Sugawara, A | 1 |
| Ito, S | 1 |
4 reviews available for candesartan and Neoplasms
| Article | Year |
|---|---|
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Contro | 2011 |
Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2011 |
[Endothelin-1, angiotensin II and cancer].
Topics: Angiogenesis Inhibitors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antineoplastic Age | 2006 |
[Stimulatory effects of angiotensin II on angiogenesis].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2006 |
1 trial available for candesartan and Neoplasms
| Article | Year |
|---|---|
Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
Topics: Age Factors; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Artery Dise | 2012 |
5 other studies available for candesartan and Neoplasms
| Article | Year |
|---|---|
Synergistic Suppression of Tumor Angiogenesis by the Co-delivering of Vascular Endothelial Growth Factor Targeted siRNA and Candesartan Mediated by Functionalized Carbon Nanovectors.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Humans; Mice; Mice, Nude; Nanotubes, | 2017 |
A chitosan-graft-PEI-candesartan conjugate for targeted co-delivery of drug and gene in anti-angiogenesis cancer therapy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cell Line, Tum | 2014 |
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; D | 2014 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; B | 2010 |
The CHARM programme.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |